Harnessing the Natural Biology of Adeno-Associated Virus to Enhance the Efficacy of Cancer Gene Therapy

Adeno-associated virus (AAV) was first characterized as small “defective” contaminant particles in a simian adenovirus preparation in 1965. Since then, a recombinant platform of AAV (rAAV) has become one of the leading candidates for gene therapy applications resulting in two FDA-approved treatments...

Full description

Bibliographic Details
Main Authors: Jacquelyn J. Bower, Liujiang Song, Prabhakar Bastola, Matthew L. Hirsch
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Viruses
Subjects:
AAV
Online Access:https://www.mdpi.com/1999-4915/13/7/1205